Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
---|---|---|---|---|---|---|---|---|---|
Croda International | BUY 3,100p→3,150p | ― | -16.80% | Reiterated | Croda International (CRDA) Receives a Buy from Barclays | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 4,600p→4,500p | ― | 2.30% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD 300p | ― | 7.30% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 2,750p | ― | 7.00% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 14,200p→14,500p | ― | 6.10% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD 9p | ― | 14.30% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY | ― | 0.80% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD 410p→360p | ― | 12.10% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL 1,400p→1,450p | ― | 10.10% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD 5,200p | ― | 1.20% | Reiterated | ||||
Oxford BioMedica | BUY 725p | ― | -16.30% | Reiterated | Oxford BioMedica: Strategic Positioning and Growth Potential in Cell and Gene Therapy | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 130p | ― | 5.60% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD 555p | ― | 19.70% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 1,350p→1,300p | ― | 10.60% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL 2,596p→2,626p | ― | 19.70% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL 10,500p | ― | 3.90% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD 1,450p | ― | 3.90% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD 1,600p | ― | 8.10% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 400p→470p | ― | 3.10% | Upgraded | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 3,489p | ― | 10.50% | Reiterated | ||||
XP Power | BUY 1,500p | ― | -4.80% | Reiterated | Berenberg Bank Reaffirms Their Buy Rating on XP Power (XPP) | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 240p | ― | 8.60% | Reiterated | ||||
Sirius Real Estate | BUY 115p | ― | -3.00% | Reiterated | Berenberg Bank Reaffirms Their Buy Rating on Sirius Real Estate (SRE) | ||||
System1 | BUY 550p | ― | -6.90% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 1,490p→1,495p | ― | 14.70% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 4,920p | ― | 8.90% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD 5,600p | ― | 2.90% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 1,150p→1,200p | ― | 20.30% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 1,220p | ― | 7.30% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 14,000p | ― | 3.80% | Reiterated | |||||
Hafsa Yasir BarclaysNot Ranked | Gore Street Energy Storage | HOLD 46.35p | ― | ― | Downgraded | Barclays downgrades Gore Street Energy Storage (GSF) to a Hold | |||
CVS Group plc | BUY 1,500p→1,900p | ― | -7.30% | Reiterated | RBC Capital Reaffirms Their Buy Rating on CVS Group plc (CVSG) | ||||
Johnson Matthey | HOLD 1,800p→2,100p | ― | -6.00% | Reiterated | Citi Keeps Their Hold Rating on Johnson Matthey (JMAT) | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 1,120p→1,160p | ― | 16.50% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD 520p | ― | 8.20% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 470p | ― | 8.20% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD 900p | ― | 10.50% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 2,650p | ― | 5.20% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD 2,600p | ― | 5.60% | Reiterated | |||||
Segro plc (REIT) | HOLD 740p | ― | -10.10% | Reiterated | we re-iterate our Hold rating | ||||
Pantheon Infrastructure PLC | BUY 112p→114p | ― | 0.50% | Upgraded | Pantheon Infrastructure PLC: Buy Recommendation Amid Discounted Valuation and Strong NAV Growth | ||||
Kainos Group plc | BUY 1,085p | ― | -19.40% | Reiterated | We group 17 countries into our ROW category with an increase in Argentina (11 open), while most of the other ROW countries show declines. Open positions in Canada, boosted by the recent acquisition, have remained fairly consistent over the year and is the third- biggest hiring country indicating further intent. The USA is the 4th largest area of hiring with 15 open positions, which has been stable since June, but is up from 10 in Dec'24. | ||||
SigmaRoc | BUY 140p | ― | -10.10% | Reiterated | SigmaRoc's Resilience and Strategic Positioning Justify Buy Rating Amid Market Challenges | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 1,500p→1,700p | ― | 8.00% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 580p | ― | 28.70% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 290p→225p | ― | 10.60% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL | ― | 9.60% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 2,700p→2,820p | ― | 7.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY 7,100p | ― | 5.60% | Reiterated | |||||
Compass | BUY 3,000p | ― | 0.10% | Reiterated | Berenberg Bank Sticks to Its Buy Rating for Compass (CPG) |